Rodman & Renshaw Reiterates Curis Market Outperform, $6 PT

Rodman & Renshaw reiterated its Curis CRIS Market Outperform / Speculative Risk rating and $6 price target in a research report published today. In the report, Rodman & Renshaw states, "With the CUDC-101 program advancing in the clinic, GDC-0449 being evaluated in inoperable BCC, the potential to secure additional milestones for both vismodegib and Debio 0932, and approximately $33 MM in cash at 2Q11, we believe Curis is an undiscovered gem in the oncology space and represents a compelling opportunity for the risk oriented, long-term investor." Shares of Curis were trading at $3.54, down 0.84% from Thursday's market close.